Several analysts have recently updated their ratings and price targets for Organogenesis (NASDAQ: ORGO):
- 3/8/2026 – Organogenesis was upgraded by Wall Street Zen from “hold” to “buy”.
- 2/28/2026 – Organogenesis was downgraded by Wall Street Zen from “strong-buy” to “hold”.
- 2/27/2026 – Organogenesis was upgraded by Weiss Ratings from “sell (d+)” to “hold (c)”.
- 2/27/2026 – Organogenesis had its price target lowered by BTIG Research from $9.00 to $8.00. They now have a “buy” rating on the stock.
Insider Buying and Selling
In other Organogenesis news, Director Michael Joseph Driscoll acquired 10,000 shares of the company’s stock in a transaction dated Monday, March 9th. The shares were acquired at an average cost of $2.67 per share, with a total value of $26,700.00. Following the acquisition, the director directly owned 225,707 shares of the company’s stock, valued at approximately $602,637.69. The trade was a 4.64% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 33.00% of the company’s stock.
Key offerings include Apligraf, a living skin substitute for treatment of diabetic foot ulcers and venous leg ulcers; Dermagraft, a cryopreserved human fibroblast-derived dermal substitute; Grafix, a placental membrane allograft for complex and chronic wounds; and TheraSkin, a cryopreserved human skin allograft used in surgical and reconstructive procedures.
Featured Articles
Receive News & Ratings for Organogenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organogenesis and related companies with MarketBeat.com's FREE daily email newsletter.
